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Abstract
Objective—The recent withdrawal of a targeted sepsis therapy has diminished pharmaceutical 
enthusiasm for developing novel drugs for the treatment of sepsis. Angiopoietin-2 is an 
endothelial-derived protein that potentiates vascular inflammation and leak-age and may be 
involved in sepsis pathogenesis. We screened approved compounds for putative inhibitors of 
angiopoietin-2 production and investigated underlying molecular mechanisms.
Design—Laboratory and animal research plus prospective placebo- controlled randomized 
controlled trial (NCT00529139) and retrospective analysis (NCT00676897).
Setting—Research laboratories of Hannover Medical School and Harvard Medical School.
Patients—Septic patients/C57Bl/6 mice and human endothelial cells.
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Interventions—Food and Drug Administration–approved library screening.
Measurements and Main Results—In a cell-based screen of more than 650 Food and Drug 
Administration–approved compounds, we identified multiple members of the 3-hydroxy-3-
methyl-glutaryl-CoA reductase inhibitor drug class (referred to as statins) that suppressed 
angiopoietin-2. Simvastatin inhibited 3-hydroxy-3-methyl-glutaryl-CoA reductase, which in turn 
activated PI3K-kinase. Downstream of this signaling, PI3K-dependent phosphorylation of the 
transcription factor Foxo1 at key amino acids inhibited its ability to shuttle to the nucleus and bind 
cis-elements in the angiopoietin-2 promoter. In septic mice, transient inhibition of angiopoietin-2 
expression by liposomal siRNA in vivo improved absolute survival by 50%. Simvastatin had a 
similar effect, but the combination of angiopoietin-2 siRNA and simvastatin showed no additive 
benefit. To verify the link between statins and angiopoietin-2 in humans, we performed a pilot 
matched case-control study and a small randomized placebo-controlled trial demonstrating 
beneficial effects on angiopoietin-2.
Conclusions—3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors may operate through a 
novel Foxo1-angiopoietin-2 mechanism to suppress de novo production of angiopoietin-2 and 
thereby ameliorate manifestations of sepsis. Given angiopoietin-2’s dual role as a biomarker and 
candidate disease mediator, early serum angiopoietin-2 measurement may serve as a stratification 
tool for future trials of drugs targeting vascular leakage.
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Despite modern antimicrobials, mortality from severe sepsis remains high at 30–50% (1). 
Dozens promising preclinical agents have failed in clinical trials. The recent market 
withdrawal of drotrecogin α following a large negative clinical trial (2) has eliminated the 
only targeted therapy for sepsis.
Angiopoietin-2 (Angpt-2) is markedly induced in sepsis, and its circulating levels are 
associated with disease severity and mortality (3–8). Largely synthesized by endothelial 
cells (ECs), premade Angpt-2 is stored in Weibel Palade bodies and rapidly released 
following inflammatory stimuli (9). During inflammation, Angpt-2 inhibits signaling 
through Tie2, a receptor expressed by ECs that is otherwise tonically active in the adult 
vasculature (10, 11). Induction of Angpt-2 sensitizes the microvasculature to inflammation 
and destabilizes quiescent ECs (12, 13). Furthermore, clinical results suggest that Angpt-2 in 
the most critically ill subjects rises not only from the release of preformed protein by 
stimulated ECs but also ongoing biosynthesis of new protein through unknown mechanisms 
(8).
Inhibition of Tie2 signaling appears to be critical for this leak-inflammation response 
because its stimulation with excess endogenous ligand, Angpt-1—or with a structurally 
unrelated peptide agonist—abrogates vascular leakage, attenuates inflammation, and 
improves survival in models of sepsis (14–16). Genetic deletion of ANGPT2 or a targeted 
antibody improves survival in experimental sepsis, ameliorates organ dysfunction, and 
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prevents vascular leakage (8, 17); protective effects are also observed in models of chronic 
infection (18).
On the basis of hypothesis that Angpt-2 may be an important mediator of septic phenotypes 
and recognizing the high barrier for bringing new drugs to market in critical illness, we 
sought inexpensive compounds with known safety profile that inhibit Angpt-2 production. 
Screening a Food and Drug Administration drug library, we identified statins, a class of 
drugs that blocks HMG-CoA reductase to lower low-density lipoprotein-cholesterol levels. 
Statins are also thought to exert important but incompletely understood effects on the 
vascular endothelium (19). Finally, given the unexplained discrepancy between beneficial 
effects in numerous preclinical models (20–22) and recent evidence suggesting lack of 
efficacy in clinical trials (23–27), we chose to investigate this drug class.
MATERIALS AND METHODS
A detailed description of the Methods is provided in the online supplement (Supplemental 
Digital Content 1, http://links.lww.com/CCM/B269).
Mouse Studies
The respective Institutional Animal Care and Use Committees approved all experiments. We 
used 8-week male C57BL/6J mice and ANGPT-2 heterozygous mice on a 129Sv/C57BL/6 
mixed background and their wild-type (WT) littermates (gift of S. Wiegand, Regeneron 
Pharmaceuticals, and Tarrytown, NY). We induced experimental sepsis either with 
lipopolysaccharide from Escherichia coli serotype O111:B4 IP or by cecal ligation and 
puncture as described previously (28). Survival was followed more than 96 hours. A subset 
of animals was euthanized 16 hours after sepsis induction for further organ analysis. When 
simvastatin was compared with a vehicle control, the drug was given at a concentration of 
0.2 µg/g body weight IP 24 hours before sepsis induction. Estimated circulating 
concentrations are reported in Supplemental Table 1 (Supplemental Digital Content 2, http://
links.lww.com/CCM/B270).
Patient Cohorts (Retrospective and Randomized Placebo Controlled Trial)
Please see online supplement (Supplemental Digital Content 1, http://links.lww.com/CCM/
B269) for details on the retrospective (NCT00529139) and prospective randomized placebo 
controlled trial (NCT00676897).
Inclusion criteria are summarized in Table 1.
Cell Culture Studies
Human umbilical vein ECs (HUVECs), human microvascular ECs, and the monocyte cell 
line U937 were cultured according to the manufacturer’s instructions. Further details 
regarding reagents and readouts are provided in the online supplement (Supplemental 
Digital Content 1, http://links.lww.com/CCM/B269).
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Molecular Analysis
Tissue (Angpt-2) and cellular (Angpt-2, von Willebrand factor [vWF], Foxo1) 
immunofluorescence were performed as previously described (8). Details on 
immunofluorescence, Western analysis, quantitative polymerase chain reaction, gel shift 
assays, and chromatin immunoprecipiation are available in the online supplement 
(Supplemental Digital Content 1, http://links.lww.com/CCM/B269) for.
Statistical Analysis
Statistical significance was evaluated by independent samples t test unless otherwise noted. 
Survival data were analyzed by log-rank test. Clinical data are presented as median (quartile 
1–quartile 3) or percentage. In the case-control study, subjects were matched for sepsis 
severity and age. Longitudinal changes of Angpt-2 in the randomized controlled trial were 
analyzed by two-sided unpaired Mann-Whitney U test. Comparison between baseline 
characteristics was calculated by Fisher exact test and Mann-Whitney U test. Spearman 
correlation was used for Angpt-2 and soluble vascular cell adhesion molecule/sESelectin. 
All experimental results are presented as mean±SEM and two-tailed p value of less than 
0.05 were considered to indicate statistical significance. Analysis and graph generation were 
performed in GraphPad Prism 6.0 (La Jolla, CA).
Study Approval
The respective Institutional Animal Care and Use Committees approved all animal 
experiments. Both human trials have been approved by the Institutional Review Boards for 
Hanover Medical School and Beth Israel Deaconess Medical Center and are registered at 
http://www.clinicaltrial.gov (NCT00529139 and NCT00676897 “Statin Therapy in the 
Treatment of Sepsis”).
RESULTS
FDA-Library Screening Identifies Simvastatin as a Potent Inhibitor of Angpt-2
ECs are the primary source of Angpt-2 in the body (29). Therefore, we applied an FDA-drug 
library for 24 hours to HUVECs and measured secreted Angpt-2 by enzyme-linked 
immunosorbent assay. Results were normalized for plate, and assay controls and are 
presented as fold versus median (Fig. 1A; Supplemental Table 2, Supplemental Digital 
Content 3, http://links.lww.com/CCM/B271). Two HMG-CoA reductase inhibitors, 
lovastatin and simvastatin, reduced Angpt-2 two- to three-fold. In vitro studies with 
simvastatin confirmed dose-dependent inhibition of Angpt-2 in different EC types with 
maximal inhibition observed at 10 µM (Fig. 1B) after 24 hours (Fig. 1C; Supplemental Fig. 
1, Supplemental Digital Content 4, http://links.lww.com/CCM/B272). Simvastatin also 
suppressed Angpt-2 produced by ECs stimulated with lipopolysaccharides, phorbol ester, or 
conditioned medium from cultured monocytes (Supplemental Fig. 2, Supplemental Digital 
Content 4, http://links.lww.com/CCM/B272). The metabolite downstream of HMG-CoA 
reductase, mevalonate, reversed simvastatin’s effect on Angpt-2 (Fig. 1D), providing 
evidence to support HMG-CoA reductase dependence rather than a pleiotropic mechanism. 
Costaining of ECs for the Weibel Palade body proteins vWF and Angpt-2 showed an initial 
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accumulation of Angpt-2 following 1 hour of simvastatin (Supplemental Fig. 3, 
Supplemental Digital Content 4, http://links.lww.com/CCM/B272), suggesting impaired 
release as previously reported (30). However, by 24 hours of simvastatin exposure, 
intraendothelial Angpt-2, but not vWF, was also depleted (Fig. 1E).
Simvastatin Reduces Angpt-2 Transcription and Binding of the Transcription Factor Foxo1 
in a PI3K/AKT-Dependent Manner
Consistent with the protein results, simvastatin dose-dependently reduced Angpt-2 mRNA 
abundance (Fig. 2A). Simvastatin was able to not only phosphorylate AKT but also required 
PI3 kinase activity to significantly suppress Angpt-2 (Supplemental Fig. 4, Supplemental 
Digital Content 4, http://links.lww.com/CCM/B272). Both, Krüppel-like factor-2 (KLF2) 
and Foxo1 have been described as potential transcriptional regulators of ANGPT2 in the 
literature (31, 32). Although simvastatin strongly induced KLF2 mRNA (Supplemental Fig. 
5A, Supplemental Digital Content 4, http://links.lww.com/CCM/B272) as previously 
reported (33, 34), knockdown of KLF2 during simvastatin exposure did not restore Angpt-2 
expression (Fig. 2B).
The 5′ region of ANGPT2 contains poorly resolved but powerful cis-elements (35). An in 
silico search revealed two putative Foxo1 binding sites (Fig. 2C; Supplemental Fig. 6, 
Supplemental Digital Content 4, http://links.lww.com/CCM/B272). We tested biotin-labeled 
and biotin-unlabeled DNA probes against these two sites in HUVEC nuclear extracts. 
Competition with six-fold excess of unlabeled probe established the specific bands of 
interest in gel shift assays (Fig. 2D). Application of simvastatin (10 µM) for 24 hours 
attenuated both bands, indicative of a decrease in bound protein (Fig. 2E). Chromatin 
immunoprecipitation with anti-Foxo1 antibody revealed significantly less binding of Foxo1 
in the ANGPT2 promoter in simvastatin-treated cells (Fig. 2F). These results show that 
Foxo1 binds to distinct regions in the 5′ region of the ANGPT2 locus and that simvastatin 
attenuates this binding.
Simvastatin Induces Foxo1 Phosphorylation
Simvastatin exposure led to Foxo1 exclusion from the nucleus (Fig. 3, A and B), an event 
that is mediated by serine/threonine phosphorylation. Indeed, simvastatin induced 
endogenous Foxo1 phosphorylation at Ser-256 (Fig. 3, C and D), as well as phosphorylation 
of ectopically expressed WT Foxo1 (Ad-Foxo1; Fig. 3, E and F). As expected, when a 
triple-phosphorylation mutant Foxo1 (Ad-TM-Foxo1, Thr-24-Ala, Ser-256-Ala, and 
Ser-319-Ala)—constitutively active with regard to its function as a transcription factor—
was expressed in ECs, phosphorylation of Foxo1 was undetectable, even in the presence of 
simvastatin (Fig. 3, G).
Foxo1 Phosphorylation Is Critical for the Suppression of Angpt-2 by Simvastatin
Transfection of ECs with control (βGal), WT Foxo1 (Ad-Foxo1), or triple-mutant Foxo1 
(Ad-TM-Foxo1) adenovirus revealed progressive induction of Angpt-2 transcript and 
released protein (Fig. 4, A and B). Cells transfected with control adenovirus and then treated 
with simvastatin (10 µM) exhibited a marked reduction in Angpt-2 (left bars). The 
suppressive effect of simvastatin was even dominant to WT Foxo1 overexpression (Ad-
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Foxo1; middle bars). In contrast, cells transfected with triple-mutant Foxo1 (Ad-TM-Foxo1) 
were completely resistant to the Angpt-2-suppressive effect of simvastatin (right bars).
Simvastatin Suppresses Angpt-2 During Sepsis and Improves Sepsis Survival
We and others have shown that Angpt-2 contributes to adverse outcomes in experimental 
sepsis (8, 17) and that simvastatin improves survival in these models (20–22). As an initial 
test for potential interactions, we found that Angpt-2 was induced in endotoxemic mice, and 
that simvastatin pretreatment (–24 hr) was able to suppress Angpt-2 induction (Fig. 5A). 
Angpt-2 heterozygous mice are protected from death and end-organ injury following 
different models of sepsis (8). In Angpt-2 heterozygotes, simvastatin did not suppress 
Angpt-2 further (Supplemental Fig. 7, Supplemental Digital Content 4, http://
links.lww.com/CCM/B272).
We then tested the interaction of simvastatin and Angpt-2 using a specific liposomal 
Angpt-2 siRNA delivery system that targets the pulmonary endothelium (36) in a 
polymicrobial model induced by cecal ligation and puncture (Fig. 5B). Simvastatin 
improved survival as anticipated (Fig. 5C, blue line). Depletion of Angpt-2 (blue dotted line) 
protected mice from sepsis-related mortality to a comparable extent as simvastatin (red line). 
But the combination of simvastatin and Angpt-2 siRNA (red dotted line) had no additive 
effect, consistent with a shared mechanism of action.
Statin Use Is Associated With Lower Circulating Angpt-2 Among Critically Ill Patients
In septic shock, eventual nonsurvivors not only have marked Angpt-2 elevation early in 
disease but also levels tend to rise even higher over time (8). To exemplary test the concept 
that statins suppress Angpt-2 in clinically meaningful contexts, we first studied a cohort of 
chronic simvastatin users (20–40 mg/d) on maintenance treatment from a previously 
published clinical trial (clinicaltrials.gov NCT00529139) who presented to medical care 
with pulmonary sepsis. Both groups had similar Acute Physiology and Chronic Health 
Evaluation II score, indicative of comparable disease severity. Subsequent inpatient 
mortality was lower in the statin group although this did not reach statistical significance. A 
higher proportion of males (39% vs 76%; p = 0.049) and a higher prevalence of pre-existing 
congestive heart failure (0% vs. 77%; p < 0.001) were present in the statin group (Table 2). 
Nonetheless, chronic statin users exhibited a lower Angpt-2 level than their counterparts 
(Fig. 6A).
To address confounding from gender distribution, heart failure, and other potential residual 
differences in the retrospective study, we then performed two independent exploratory 
randomized placebo-controlled trials in which statin-naïve patients presenting with sepsis to 
the emergency department received either simvastatin 40 mg orally once daily or a placebo 
pill. Because of the small numbers in each trial and the comparable study designs, the results 
were analyzed in aggregate. Baseline characteristics did not differ between treatment groups 
(Table 3), and there was only one death. To assess the safety of this intervention, we tested 
liver function (alanine transaminase or aspartate transaminase) and creatine phosphokinase 
levels at baseline and at 48 hours post initiation of statin therapy. We found that these levels 
were similar in both groups (all p > 0.05) and that none rose into the abnormal range. We 
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observed a significant reduction in circulating Angpt-2 over time and a trend toward 
improved tumor necrosis factor-α levels in the statin group (Fig. 6, B and C). Consistent 
with the concept that Angpt-2 is an upstream mediator of endothelial inflammation (12), the 
change in Angpt-2 over time was strongly associated with the change in soluble vascular 
cell adhesion molecule-1 (r = 0.50; p = 0.01) and sEselectin (r = 0.54; p = 0.006).
DISCUSSION
Using an unbiased screen, we found that statins attenuated the production of Angpt-2 by 
ECs, an emerging mechanistic target in sepsis-related vascular leakage (3, 8). Subsequent 
cellular studies revealed a novel mechanism of statin action in the endothelium, ie, 
phosphorylation of the transcription factor Foxo1 that prevents its nuclear translocation and 
subsequent binding to the ANGPT2 promoter. Studies in septic WT and Angpt-2 
heterozygous mice revealed the physiological significance of statin-mediated Angpt-2 
suppression. Finally, the potential medical impact of these findings was exemplified by two 
independent studies of individuals hospitalized with critical illness.
Since the initial reports of statin benefits in preclinical sepsis models (20–22), a number of 
putative molecular mechanisms have been identified, involving the endothelium and other 
cell types (summarized in [37]). Among the several endothelial pathways implicated in 
sepsis, results from Angpt-2 overexpression studies, chemically inflamed and septic Angpt-2 
knockout mice, and infected mice treated with an Angpt-2–neutralizing antibody all strongly 
suggest that this molecule is a major effector of the vascular pathophysiology in sepsis (3, 8, 
12, 17, 18, 38). Furthermore, these loss- and gain-of-function experimental findings have 
been corroborated by more than 20 independent clinical studies in sepsis and related 
diseases (summarized in [39]). Interestingly, Angpt-2 appears to be both a potent biomarker 
of outcome and a promising candidate disease mediator. Therefore, although statins clearly 
have multiple vascular and nonvascular salutary effects, the importance of Angpt-2 in sepsis 
is supported by a large body of independently reported experimental and human evidence.
Seeking pathways beyond lipid-lowering to account for statin benefits in cardiovascular 
disease, Kureishi et al (40) observed activation of endothelial nitric oxide synthase (eNOS) 
and statin-induced angiogenesis in a chronic ischemia mouse model, and Pleiner et al (41) 
showed simvastatin-dependent preservation of endothelial-NO-dependent flow responses. 
However, eNOS-null mice respond to different noxious stimuli with less vascular leakage 
and less cellular inflammation, arguing against a putative statin-eNOS mechanism of benefit 
in experimental sepsis. Focusing on vascular permeability, groups led by Jacobsen and van 
Niew Amerongen independently found that endothelial monolayers pretreated with 
simvastatin fortify barrier function against inflammatory mediators of permeability (19, 42). 
Statins appear to remodel the endothelial cytoskeleton and intercellular junctions to tighten 
the barrier by using the same Rho family GTPases that are modulated downstream of the 
Angpt-2 receptor, Tie2 (3, 8, 14, 43, 44).
In experimental sepsis, Angpt-1 is reduced, Angpt-2 is induced, and the phosphorylation of 
Tie2 and Akt are reduced (14). Activation of Tie2 by Angpt-1 leads to Akt-mediated Foxo1 
phosphorylation at both Ser-256 and Thr-24 and a consequent reduction in Angpt-2 (31). 
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Presently, simvastatin induced phosphorylation of Foxo1 at Ser-256 and Thr-24 and reduced 
Foxo1 binding to the ANGPT2 promoter. Together, the results support a mechanism in 
which statin-mediated Foxo1 phosphorylation retards the nuclear trafficking of Foxo1 and 
inhibits its DNA binding to the ANGPT2 promoter. Given the recent demonstration that the 
global knockout of Foxo1 is rescued by EC-specific reconstitution, statin-dependent 
modulation of Foxo1 may exert its most potent impact on the endothelium (45). Perhaps not 
surprisingly, Angpt-2 was one of the most reliable indicators of Foxo1 activity in both the 
gain- and the loss-of-function mouse models reported by Dharaneeswaran et al (45).
Synthesizing the present results, the transition from healthy to septic vasculature may be 
instigated by an initial reduction in Tie2 signaling driven by the cytokine-mediated rapid 
release of preformed Angpt-2 protein (9). Impairment of Tie2 signaling, in turn, relieves the 
otherwise tonic suppression of Foxo1, leading to sustained Angpt-2 biosynthesis that further 
destabilizes blood vessels toward a leaky, inflammatory phenotype (Fig. 7). Although the 
cytokine-dependent release of preformed Angpt-2 protein is well-known (9), serial Angpt-2 
measurements from critically ill patients clearly suggest that the sickest patients exhibit 
ongoing Angpt-2 production (3, 8). Because Angpt-2 antagonizes Tie2 in the context of 
inflammation, a profound initial release of preformed Angpt-2 could initiate a feedback loop 
that sustains (and perhaps amplifies) the deleterious state of Tie2 signaling impairment. 
Thus, primary prevention of Angpt-2 induction may be more effective clinically than efforts 
to intervene after an Angpt-2/Tie2 feedback loop has been established. Intriguingly, 
approximately 40 human studies suggest an association between chronic prior statin use and 
improved outcomes among patients with infection (summarized in [46]), whereas the results 
of acutely administered statins have been mixed or even negative (24–27, 46). In our mouse 
studies, 24-hour pretreatment with statins was intended to model chronic dosing because this 
duration of treatment potently reduced Angpt-2 expression in vitro.
Several questions merit further investigation. First, the pharmacology of statins in sepsis is 
problematic because first-pass metabolism, particularly after oral administration, limits 
systemic endothelial availability. Therefore, the present results should spur new thinking 
about ways to deliver existing statin drugs to the endothelium (eg, nanoparticles) or consider 
novel pharmacological approaches to targeting pulmonary endothelial HMG-CoA reductase. 
Second, there may be additional mechanistic links, such as statin-driven regulation of 
Foxo1-modulating serine-threonine phosphatases and the prevalence of Foxo1 mutancy. 
Third, although our in vivo results argue that Angpt-2 is a major effector down-stream of 
simvastatin in sepsis, additional studies are needed to address the contribution of Angpt-2 to 
the chronic cardiovascular effects of statins. Finally, the trial results presented here help 
address some of the shortcomings of our own retrospective analysis, but both investigations 
merit larger and better-powered follow-up studies that focus on Angpt-2 as a potential 
stratifier for statin benefit.
CONCLUSIONS
The present results elucidate the molecular apparatus that sustains ongoing Angpt-2 
biosynthesis in the septic endothelium. Through an unbiased approach, they identify statins 
as potential inhibitors of Angpt-2 and propose a novel mechanism for this widely used drug 
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class. In the setting of recent negative clinical trial results with statins in ICU situations, our 
results offer two concrete implications—first, pharmacologically attenuating the Angpt-2-
Tie-2 feedback loop may require a preventative approach; and second, early (point of care) 
measurement of circulating Angpt-2 levels may help stratify subjects responsive to 
adjunctive statin treatment for future clinical trials.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Food and Drug Administration (FDA) library screening identifies simvastatin (SIM) as a 
potent inhibitor of Angpt-2 production. A, Human umbilical vein endothelial cells 
(HUVECs) grown in a 96-well format were treated with an FDA-drug library for 24 hr, and 
secreted Angpt-2 protein was measured by enzyme-linked immunosorbent assay (ELISA). 
Results were analyzed as the fold-change relative to the median value and ordered from 
strongest inducers (left, blue bars) to strongest inhibitors (right, red bars). The yellow 
window spans ±1-fold change. B, Simvastatin (SIM, 10 µM) was applied to HUVECs for 24 
hr at indicated doses and secreted Angpt-2 protein was measured by ELISA. C, Simvastatin 
(10 µM) was applied to HUVECs for indicated durations, after which Angpt-2 protein levels 
in the conditioned media were measured by ELISA *p < 0.05, **p < 0.01. D, HUVECs were 
treated with SIM (10 µM) or an excess of mevalonate (MEV, 200 µM), and secreted 
Angpt-2 protein was measured by ELISA. *p < 0.05, **p < 0.01, and ***p < 0.001. E, 
HUVECs were stained for Angpt-2 (green) and a marker of Weibel Palade bodies (ie, von 
Willebrand Factor, red) 24 hr after vehicle or SIM (10 µM) treatment.
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Figure 2. 
Simvastatin reduces angiopoietin-2 (Angpt-2) transcription and binding of the transcription 
factor Foxo1. A, Angpt-2 mRNA concentrations were measured via real-time polymerase 
chain reaction (RT-PCR) 24 hr after applying simvastatin (SIM) at indicated concentrations 
to human umbilical vein endothelial cells (HUVECs). B, SIM (10 µM) was applied for 24 hr 
to HUVECs pretreated with control or Krüppel-like factor-2 (KLF2) siRNA and Angpt-2 
mRNA was measured by RT-PCR. C, Putative Foxo1 binding sites were identified at –2,840 
and –1,660 in the three kilobases 5′ to the translational start site of human ANGPT2 by 
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TFsearch and cross-checked by aligning the consensus Foxo1 binding sequence (in bold). D, 
Nuclear extracts of HUVECs were incubated with biotin labeled DNA probes specific for 
the –2,840 and –1,660 sites of ANGPT2 in the presence (+) or absence (−) of six-fold excess 
unlabeled probes. Arrows indicate the specific band eliminated by competition. E, Nuclear 
extracts of HUVECs either treated with vehicle (−) or SIM (10 µM, +) for 24 hr were 
prepared and incubated with biotin-labeled DNA probes specific for the –2,840 and –1,660 
sites of ANGPT2. Arrows indicate the band of interest and arrowhead indicates a non-
specific band. F, HUVECs treated with SIM (10 µM) for 24 hr were gently lysed and 
chromatin immunoprecipitation was performed with anti-Foxo1. Results of RT-PCR to 
quantify ANGPT2 promoter concentration are shown for the –2,840 and –1,660 sites. *p < 
0.05, ***p < 0.001.
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Figure 3. 
Simvastatin prevents nuclear Foxo1 translocation by phosphorylation. A, Endothelial cells 
(ECs) treated with simvastatin (SIM, 10 µM) were stained for Foxo1 (red) and nuclei (4',6-
diamidino-2-phenylindole, blue). White arrows indicate the edge of nuclear staining. B, 
Planimetric quantification of staining results by surveying 10 high-powered fields (×40) per 
slide. *p < 0.05 and **p < 0.01. C, HUVEC lysates 24 hr after SIM treatment (10 µM) were 
immunoblotted with anti-pSer256-Foxo1 (pFoxo-1), anti-Foxo1 (tFoxo-1), and anti-GAPDH 
as a loading control. D, Densitometric quantification of the above results. E, 
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Immunoblotting as described above for lysates of ECs infected with a virus encoding wild-
type Foxo1 (AdFoxo1) for 24 hr and treated with SIM (10 µM) for 24 hr or vehicle. F, 
Quantification of the above results. G, Immunoblotting as described above for lysates of 
ECs infected with a virus encoding triple-phosphorylation mutant Foxo1 (TM Foxo1) before 
24-hr treatment with SIM (10 µM) or vehicle. *p < 0.05.
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Figure 4. 
Foxo1 phosphorylation is critical for the suppression of Angpt-2 by simvastatin. A, Real-
time polymerase chain reaction for Angpt-2 24 hr after treating virally transduced human 
umbilical vein endothelial cells with simvastatin (SIM, 10 µM) or vehicle. “βGal” is a 
control virus expressing β-galactosidase; “AdFoxo1” is a virus encoding wild-type Foxo1; 
and “Ad-TM-Foxo1” is a virus encoding the triple phosphorylation constitutively active 
mutant Foxo1. B, ELISA for secreted Angpt-2 protein for the above conditions. *p < 0.05, 
**p < 0.01, ***p < 0.001, and ****p < 0.0001.
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Figure 5. 
Simvastatin (SIM) suppresses Angpt-2 during sepsis and improves sepsis survival. A, Adult 
male C57BL/6 mice treated with SIM (0.2 µg/g body weight [BW] IP) or vehicle (Veh) 24 
hr before the injection with gram-negative endotoxin (lipopolysaccharides [LPS] from 
Escherichia coli IP) or saline control. Angpt-2 mRNA was measured 16 hr after LPS by 
real-time polymerase chain reaction (RT-PCR) in lung homogenates. (n = 4–9 mice per 
group, **p < 0.01). B, Angpt-2 mRNA was measured by quantitative RT-PCR from murine 
lungs 48 hr after treatment with an Angpt-2 or control siRNA specifically targeting the 
pulmonary endothelium (n = 9 mice per group, **p < 0.01). C, Adult male C57BL/6 mice (n 
= 10 mice per each of the four study arms) were treated with SIM (200 µg/kg BW IP) versus 
Ghosh et al. Page 18
Crit Care Med. Author manuscript; available in PMC 2016 July 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
vehicle solution and control siRNA versus Angpt-2 siRNA as described in the Materials and 
Methods section. Survival after cecal ligation and puncture (CLP) was followed. **p < 0.01 
by log-rank test for all conditions versus animals treated with control siRNA and vehicle. 
Survival following CLP was statistically indistinguishable among the remaining groups.
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Figure 6. 
Chronic or acute statin use is associated with lower circulating Angpt-2 among critically ill 
patients. A, Circulating Angpt-2 concentration at the time of enrollment in a case-control 
study of critically ill subjects comparing chronic statin users versus statin-naïve individuals. 
B, Change in circulating Angpt-2 over the first 48–72 hr after randomization in a placebo 
controlled clinical trial of statin-naïve septic individuals receiving 40 mg simvastatin orally 
once daily or placebo pill (*p < 0.05 and **p < 0.01).
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Figure 7. 
Proposed mechanism for statin-mediated suppression of ongoing Angpt-2 production during 
sepsis. In endothelium of quiescent blood vessels, Tie2 is tonically expressed and activated. 
Through downstream activation of Akt, Foxo1 is phosphorylated and Angpt-2 transcription 
is suppressed. During the initial phase of sepsis, pre-formed Angpt-2 stored in Weibel 
Palade bodies (WPBs) is rapidly exocytosed in response to early acute-phase cytokines. 
Excess Angpt-2 impairs Tie2 signaling, which in turn, reduces Foxo1 phosphorylation and 
enables it to drive the transcription of the ANGPT2 gene. Simvastatin favors the 
phosphorylation of Foxo1, thus attenuating the production of Angpt-2.
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Table 1
Enrollment Criteria for Sepsis-Simvastatin Randomized Trials
Adult (> 18 yr) patients Concomitant statin, cyclosporine or digoxin use
Confirmed or suspected infection Pregnant
Two or more systemic inflammatory response syndrome criteria: Liver transaminase elevation > 3× normal
  Temperature > 100.4°F or < 96.8°F Creatinine phosphokinase > 6× normal
  Heart rate > 90 bpm Unable to take enteral medication
  Respiratory rate > 20 breaths/min or
  Oxygen saturation < 90% on supplemental oxygen
  White blood cell count > 12,000 or < 4,000 cells/µL or > 10% bandemia
NB: for the septic shock cohort, shock was defined as vasopressor use > 1 hr
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Table 2
Baseline Characteristics of Retrospective Case-Control Study
Characteristics No Statin (n = 13) Statin (n = 13) p
Age (yr) 51 (36–62) 56 (47–63) 0.64
Men (%) 39 76 0.049
Race (% Caucasian) 100 100 1.0
Comorbidity (%)
  Congestive heart failure 0 77 < 0.001
  Prior stroke/transient ischemic attack 8 0 0.31
  Chronic lung disease 15 31 0.35
  Chronic kidney disease 46 38 0.69
  Cancer 8 0 0.31
  Diabetes 46 23 0.21
Disease severity at enrollment
  Acute Physiology and Chronic Health Evaluation II 31 (27–34) 30 (27–34) 0.97
  Lactate (mg/dL) 2.8 (1.7–4.8) 4.4 (1.5–10.5) 0.48
In-hospital mortality (%) 46.2 15.4 0.096
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Table 3
Baseline Characteristics of the Simvastatin Randomized Placebo-Controlled Clinical Trial
Characteristics Placebo (n = 15) Simvastatin (n = 11) p
Age (yr) 54 (47–62) 56 (53–72) 0.11
Males (%) 27 45 0.42
Race (% Caucasian) 80 91 1.0
Comorbidity (%)
  Congestive heart failure 13 18 1.0
  Prior stroke/transient ischemic attack 27 0 0.11
  Chronic lung disease 13 27 0.62
  Chronic kidney disease 33 18 0.66
  Cancer 7 36 0.13
  Diabetes 20 9 0.61
Sepsis severity at enrollment
  Acute Physiology and Chronic Health Evaluation II 18 (3–20) 16 (9–21) 0.46
  Lactate (mg/dL) 1.9 (1.3–2.4) 2.5 (1.5–3.1) 0.11
In-hospital mortality (%) 6 0 1.0
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